Rovers KP, Bakkers C, Nienhuijs SW, et al. - Results of this phase 2 trial support the feasibility as well as safety of administering perioperative systemic therapy in patients diagnosed with resectable colorectal peritoneal metastases (CPM); this justifies a phase 3 trial.

• An open-label, parallel-group phase 2 randomized clinical trial was performed in 9 Dutch tertiary centers.

• The analysis was performed including 79 patients randomized to perioperative systemic therapy (experimental arm) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone (control arm).

• No significant difference was there between the trial arms regarding the proportions of macroscopic complete cytoreductive surgery (experimental arm, 89%; control arm, 86%) and major postoperative morbidity (experimental arm, 22%; control arm, 33%).

• Per findings, perioperative systemic therapy appeared feasible, safe, and able to induce response of CPM